pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,322 catalysts · 4,728 grant · 4,531 device 510k · 3,606 8k filing · 3,224 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-31: 3 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: recall×from 2024-11-18×clear all
type
  • grant4,728
  • device 510k4,531
  • 8k filing3,606
  • approval3,224
  • device pma2,000
  • device recall2,000
recall
1,098
  • device adverse event1,000
  • earnings585
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Nov 18, 2024

    33
    ›Nov 19, 2024approval651d agoQSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval(phentermine hydrochloride + topiramate) ER

    Sponsor: VIVUS LLC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →(phentermine hydrochloride + topiramate) ER →fda approvals ↗
    ›Nov 19, 2024approval651d agoPAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approvalPAXLOVID (COPACKAGED)

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →PAXLOVID (COPACKAGED) →fda approvals ↗
    ›Nov 20, 2024approval650d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Nov 20, 2024approval650d agoADRENACLICK (EPINEPHRINE) — FDA approvalViatris Inc

    Sponsor: IMPAX. Form: INJECTABLE. Route: INTRAMUSCULAR, SUBCUTANEOUS

    full page →fda approvals ↗
    ›Nov 20, 2024approval650d agoOXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: SANALUZ. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 20, 2024approval650d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: SANALUZ. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 20, 2024recall650d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls III)Teva Pharmaceuticals USA Inc

    Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61. — Reason: Failed Impurities/Degradation Specifications; during routine stability testing for impurities. — Status: Terminated

    full page →fda recalls ↗
    ›Nov 20, 2024recall650d agoCipla USA, Inc. recall (Cls II)Cipla USA Inc

    Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98 — Reason: Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 20, 2024recall650d agoTrinity Gold Nutrition recall (Cls II)IGC Pharma, Inc.

    Trinity Gold Nutrition, 60 Capsule, 30 day Supply, Distributed by Trinity Gold Nutrition 201 Tom Hall St. Ste. 2107, Fortmill, SC 29716, USA, Ph: 704-629-8203, www.trinitygold.com, Made in India, UPC 802992001009 — Reason: Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared acetaminophen, diclofenac and phenylbutazone. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 20, 2024recall650d agoKeystone Industries recall (Cls II)

    Perio Maintenance Rinse 0.63% Stannous Fluoride Concentrated Solution, Rx Only, Net Wt. 10 oz. (283.5 g) pumps, Mint flavor, Manufactured by: Keystone Industries, 480 S. Democrat Rd., Gibbstown, NJ 08027, NDC 68400-202-10 — Reason: Subpotent Drug — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 20, 2024recall650d agoCipla USA, Inc. recall (Cls II)Cipla USA Inc

    Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Exelan Pharmaceuticals, NDC 76282-0478-90 — Reason: Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 21, 2024approval649d agoLICART (DICLOFENAC EPOLAMINE) — FDA approvalAmzell Limited

    Sponsor: IBSA INST BIO. Form: SYSTEM. Route: TOPICAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoCALDOLOR (IBUPROFEN) — FDA approvalCUMBERLAND PHARMACEUTICALS INC

    Sponsor: CUMBERLAND PHARMS. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoDICLOFENAC SODIUM — FDA approvalDICLOFENAC SODIUM

    Sponsor: AUROBINDO PHARMA USA. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →DICLOFENAC SODIUM →fda approvals ↗
    ›Nov 21, 2024approval649d agoPONSTEL (MEFENAMIC ACID) — FDA approvalAvion Pharmaceuticals LLC

    Sponsor: AVION PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoOXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approvalMidol

    Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: ORAL

    full page →Midol →fda approvals ↗
    ›Nov 21, 2024approval649d agoBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approvalNovitium Pharma LLC

    Sponsor: STEVENS J. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoOXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approvalMidol

    Sponsor: BARR LABS INC. Form: TABLET. Route: ORAL

    full page →Midol →fda approvals ↗
    ›Nov 21, 2024approval649d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalhydrocodone bitartrate ER

    Sponsor: STRIDES PHARMA. Form: TABLET. Route: ORAL

    full page →hydrocodone bitartrate ER →fda approvals ↗
    ›Nov 21, 2024approval649d agoPERCODAN (ASPIRIN) — FDA approvalEndo Pharmaceuticals Inc

    Sponsor: ENDO OPERATIONS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalANI PHARMACEUTICALS INC

    Sponsor: ANI PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approvalBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

    Sponsor: NOVITIUM PHARMA. Form: CAPSULE. Route: ORAL

    full page →BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE →fda approvals ↗
    ›Nov 21, 2024approval649d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalStrides Pharma Inc

    Sponsor: ACTAVIS LABS FL INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoSYNALGOS-DC (ASPIRIN) — FDA approvalBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

    Sponsor: SUN PHARM INDUSTRIES. Form: CAPSULE. Route: ORAL

    full page →BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE →fda approvals ↗
    ›Nov 21, 2024approval649d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalStrides Pharma Inc

    Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalStrides Pharma Inc

    Sponsor: AMNEAL PHARMS NY. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 21, 2024approval649d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalhydrocodone bitartrate ER

    Sponsor: AUROLIFE PHARMA LLC. Form: TABLET. Route: ORAL

    full page →hydrocodone bitartrate ER →fda approvals ↗
    ›Nov 21, 2024approval649d agoCARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE (ASPIRIN) — FDA approvalCosette Pharmaceuticals Inc

    Sponsor: INGENUS PHARMS NJ. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 22, 2024approval648d agoTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalteclistamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →teclistamab →fda approvals ↗
    ›Nov 22, 2024approval648d agoRAPIBLYK (LANDIOLOL HYDROCHLORIDE) — FDA approvalAOP Health

    Sponsor: AOP HLTH US. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Nov 22, 2024approval648d agoHYDROCODONE BITARTRATE AND ASPIRIN (ASPIRIN) — FDA approvalPurdue Pharma LP

    Sponsor: LGM PHARMA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 22, 2024approval648d agoLUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approvalmosunetuzumab

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →mosunetuzumab →fda approvals ↗
    ›Nov 22, 2024approval648d agoVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalCARIPRAZINE HYDROCHLORIDE

    Sponsor: ABBVIE. Form: CAPSULE. Route: ORAL

    full page →CARIPRAZINE HYDROCHLORIDE →fda approvals ↗

    Week of Nov 25, 2024

    17
    ›Nov 25, 2024approval645d agoSUNLENCA (LENACAPAVIR SODIUM) — FDA approvallenacapavir sodium LA

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →lenacapavir sodium LA →fda approvals ↗
    ›Nov 25, 2024approval
    ← prev
    page 1 of 87
    next →
    645d ago
    SUNLENCA (LENACAPAVIR SODIUM) — FDA approvallenacapavir sodium LA

    Sponsor: GILEAD SCIENCES INC. Form: TABLET. Route: ORAL

    full page →lenacapavir sodium LA →fda approvals ↗
    ›Nov 26, 2024approval644d agoCHILDREN'S ZYRTEC HIVES (CETIRIZINE HYDROCHLORIDE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Nov 26, 2024approval644d agoRALDESY (TRAZODONE HYDROCHLORIDE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KAMAT. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Nov 27, 2024approval643d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Nov 27, 2024recall643d agoPadagis US LLC recall (Cls III)Padagis LLC

    Triamcinolone Acetonide Cream USP, 0.025%, 1 LB (454 g) per jar, Rx Only, Manufactured By Padagis, Minneapolis, MN 55427. NDC: 45802-0063-05 — Reason: Subpotent and Superpotent Drug. Out of specification assay results recorded as part of Uniformity of Container test during long-term stability testing. — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoLupin Pharmaceuticals Inc. recall (Cls II)LB PHARMACEUTICALS INC

    Ramipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68180-591-01), and c) 500 count (NDC 68180-591-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India — Reason: CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoDr. Reddy's Laboratories, Inc. recall (Cls III)DR REDDYS LABORATORIES LTD

    IBU (ibuprofen) 600 mg tablets, 500-count bottle, Rx Only, Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540, Made in India, NDC 55111-683-05 — Reason: Failed Tablet/Capsule Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)Moberg Pharma AB

    Guaifenesin Dextromethorphan Syrup, 100 mg/10mg per 5 mL, Major Pharmaceuticals 8401 Bearing Drive, Suite 100, Indianapolis, IN, 46268, NDC 0904-7134-70 — Reason: Failed Impurity/Degradation Specifications — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)Moberg Pharma AB

    Guaifenesin Dextromethorphan Syrup, 200 mg/20mg per 10 mL, Major Pharmaceuticals 8401 Bearing Drive, Suite 100, Indianapolis, IN, 46268, NDC 0904-7135-72 — Reason: Failed Impurity/Degradation Specifications — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoSafecor Health, LLC recall (Cls II)Aspire Biopharma Holdings, Inc.

    Aspirin Chewable tablet 81 mg, 1 tablet in blister card-foils, 100-count unit dose box, www.safecorhealth.com, NDC 48433-129-01 — Reason: cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoSafecor Health, LLC recall (Cls II)

    Calcium Carbonate Chewable 500 mg, 1 tablet in blister card-foils, 100-count unit dose box, www.safecorhealth.com, NDC 48433-106-01 — Reason: cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoTailstorm Health INC recall (Cls II)F. Hoffmann-La Roche Ltd

    BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syringe, Rx Only, Repackaged by: Medivant Healthcare: 24416 N 19th Ave, Phoenix, AZ, NDC 81483-0041-1 — Reason: Lack of Sterility Assurance — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoLupin Pharmaceuticals Inc. recall (Cls II)LB PHARMACEUTICALS INC

    Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India — Reason: CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoLupin Pharmaceuticals Inc. recall (Cls II)LB PHARMACEUTICALS INC

    Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India — Reason: CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor — Status: Terminated

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoSafecor Health, LLC recall (Cls II)

    Docusate Sodium 250 mg, 1 Softgel in blister card-foils, 100-count unit dose box, www.safecorhealth.com, NDC 48433-101-01 — Reason: cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 27, 2024recall643d agoNoven Pharmaceuticals Inc recall (Cls II)NRX Pharmaceuticals, Inc.

    Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30 individually sealed transdermal patches, inside a foil-sealed polypropylene tray, packed in a paper carton/box, MANUFACTURED BY NOVEN PHARMACEUTICALS, INC., Miami, FL 33186 United Sates, NDC 68968-0215-3 — Reason: Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive). — Status: Ongoing

    full page →fda recalls ↗
    $IGC0.2670+0.41%
    $CPIX8.4600-2.20%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $PFE27.96-0.21%
    $VTRS16.34-3.26%
    $BLNC
    $GILD145.68-2.14%
    $ANIP72.83-0.93%
    $ABBV255.48-1.03%
    $GILD145.68-2.14%
    $KVUE19.17-0.16%
    $LBRX47.73-0.33%
    $RDY12.18+0.16%
    $LBRX47.73-0.33%
    $ASBP
    $NRXP
    $LBRX47.73-0.33%